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Abstract
In acute promyelocytic leukemia (APL), hematopoietic differentiation is blocked and immature blasts accumulate in the
bone marrow and blood. APL is associated with chromosomal aberrations, including t(15;17) and t(11;17). For these two
translocations, the retinoic acid receptor alpha (RARa) is fused to the promyelocytic leukemia (PML) gene or the
promyelocytic zinc finger (PLZF) gene, respectively. Both fusion proteins lead to the formation of a high-molecular-weight
complex. High-molecular-weight complexes are caused by the ‘‘coiled-coil’’ domain of PML or the BTB/POZ domain of PLZF.
PML/RARa without the ‘‘coiled-coil’’ fails to block differentiation and mediates an all-trans retinoic acid-response. Similarly,
mutations in the BTB/POZ domain disrupt the high-molecular-weight complex, abolishing the leukemic potential of PLZF/
RARa. Specific interfering polypeptides were used to target the oligomerization domain of PML/RARa or PLZF/RARa. PML/
RARa and PLZF/RARa were analyzed for the ability to form high-molecular-weight complexes, the protein stability and the
potential to induce a leukemic phenotype in the presence of the interfering peptides. Expression of these interfering
peptides resulted in a reduced replating efficiency and overcame the differentiation block induced by PML/RARa and PLZF/
RARa in murine hematopoietic stem cells. This expression also destabilized the PLZF/RARa-induced high-molecular-weight
complex formation and caused the degradation of the fusion protein. Targeting fusion proteins through interfering
peptides is a promising approach to further elucidate the biology of leukemia.
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Introduction
Acute myeloid leukemia (AML) is characterized by an
accumulation of progenitor blasts in the bone marrow. These
blasts are blocked in their differentiation and are characterized by
an aberrant ‘‘self-renewal’’ [1]. Acute promyelocytic leukemia
(APL) is a well-characterized subtype of AML with the specific
t(15;17) and t(11;17) translocations, which are considered indis-
pensable for the leukemic phenotype [1].
The t(15;17) and t(11;17) translocations involve the same
domain of the retinoic acid receptor alpha (RARa) fused to
PML or PLZF, respectively. Ectopic expression of PML/RARa
and PLZF/RARa in hematopoietic cells mimics the leukemic
phenotype by inducing a differentiation block and an aberrantly
activated self-renewal capability, leading to the development of
leukemia in mice [2,3]. The biological activities of these fusion
proteins have yet to be completely elucidated. One proposed
mechanism suggested that the inhibition of differentiation-
associated transcription factors could occur by direct binding,
such as VDR and PU.1, leading to their sequestration [4,5].
Treatment with ATRA (all-trans retinoic acid) is able to overcome
the differentiation block in PML/RARa-expressing blasts but not
in PLZF/RARa-positive-blasts [6]. In vivo PML/RARa forms
high-molecular-weight (HMW) complexes through the ‘‘coiled-
coil’’ region of PML [7]. Furthermore, the PML ‘‘coiled-coil’’
region of PML/RARa is required to block the terminal
differentiation in PML/RARa positive blasts [7,8]. Treatment
with ATRA disrupt the formation of HMW complexes by PML/
RARa [9]. PLZF/RARa is able to form HMW complexes
through the BTB/POZ domain [9]. Crystallization studies on the
BTB/POZ domain showed that the POZ domain exhibits a
structure that enables the formation of homodimers, which assume
a quaternary structure to form a multimeric complex [10,11].
Another common feature of both PML/RARa and PLZF/
RARa is the formation of stable complexes with the HD-NCR
(histone deacetylase recruiting nuclear co-repressor complex). Both
fusion proteins bind to the members of the HD-NCR, N-CoR and
SMRT through the CoR box region of RARa. This binding is
ligand-dependent, as shown by the release after treatment with
pharmacological doses of ATRA. In contrast to PML/RARa,
PLZF/RARa contains a second binding site for the members of
the HD-NCR in the PLZF portion of the fusion protein. This
binding is ATRA-resistant and is mainly located in the POZ
domain [6,12]. The BTB/POZ domain has been shown to bind to
SMRT, mSin3A and HDAC-1, all mediators of the transcriptional
repression, in a ligand-independent manner [6]. The aberrant
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ATRA-induced genes, which are responsible for the differentiation
of hematopoietic precursor cells. The critical residues for both the
interaction with the HD-NCR as well as the capacity to form
HMW complexes were exactly mapped to the BTB-POZ domain
[11]. Furthermore, we have shown that the BTB/POZ domain
mediates the oligomerization of PLZF/RARa. Point mutations in
the BTB/POZ, which interfere either with the correct folding or
with the charge of the pocket formed between the two POZ
subunits, are able to inhibit the function of both PLZF and PLZF/
RARa. These point mutations, which inhibit oligomerization,
abolish the PLZF/RARa-related differentiation block and the
aberrant self-renewal of PLZF/RARa-positive hematopoietic stem
cells (HSCs) [13].
In this work, we tested whether we could target the
oligomerization domain of PML/RARa or PLZF/RARa with
interfering polypeptides that represent the respective oligomeriza-
tion regions in PML and PLZF (PCC and POZ, respectively). We
showed that the co-expression of the interfering peptides overcame
the differentiation block induced by PML/RARa and PLZF/
RARa (X-RARa, where X corresponds either to PML or PLZF)
in murine hematopoietic stem cells, resulting in a reduced
replating efficiency of the X-RARa-expressing HSCs in the same
system. The peptides were able to bind to the fusion protein and
modify the HMW complex formed by each X-RARa.I n
conclusion, specific molecular targeting by interfering with the
oligomerization of the APL fusion proteins demonstrates a proof of
principle for a promising therapeutic approach and represents an
effective tool to further understand the biology of leukemia.
Design and Methods
Plasmids
The methods for the cDNAs encoding PCC, POZ and GFP
were previously described [14]. Megaprimers were designed for
the amplification and further subcloning of PCC/POZ-GFP using
PCR. Megaprimer 1 contained the complete PCC/POZ and




Megaprimer 2 contained the complete GFP and flanking PCC/






TCAGGC]. These megaprimers were further used to synthesize
PCC/POZ-GFP using PCR. These sequences were inserted into
the PIDE vector by digestion with the HindIII restriction
enzyme.
The pE-PCC-ABL, pE-POZ-ABL, pE-GFP, pE-PML/RARa
and pE-PLZF/RARa vectors for Gateway insertion of the fusion
protein were described previously [13,15]. For further subcloning
of the cDNAs into different expression vectors, the Gateway
recombination system (Invitrogen, Munich, Germany) was used.
All cDNA sequences were cloned in the pENTR1A vector and
shuttled with the LRClonase-Enzyme Kit (Invitrogen, Munich,
Germany) into plasmids previously converted to Gateway desti-
nation vectors according to the manufacturer’s instructions. For
the immunoprecipitation experiments, we used a pCDNA3-
derived vector to transiently express PML/RARa, PML/RARa
or the peptides HA-PCC, HA-POZ, HA-PCC or HA-empty
under the control of a CMV promoter. For retroviral transduc-
tion, we used the PINCO retroviral vector [16] and its derivative
PIDE to generate PCC/POZ-GFP. The transgene expression was
driven by the LTR and the expression of the enhanced green
fluorescence protein (eGFP) [17] or the GFP fusion protein, under
the control of the CMV promoter. PML3-160/RARa, in which
the three SUMO-binding sites were mutated was graciously
provided by Thomas Sternsdorf.
Cell lines, cell culture and western blotting
Phoenix ecotropic packaging cells (Orbigen, San Diego, USA)
were maintained in DMEM supplemented with 10% FCS
(Invitrogen, Munich, Germany), 1% penicillin/streptomycin and
1% L-glutamine (Gibco-BRL, Invitrogen, Munich, Germany).
BA/F3 (ACC-300 DSMZ) cells were maintained in RPMI
supplemented with 10% FCS, 1% penicillin/streptomycin, 1%
L-glutamine and mIL-3 (20 ng/ml) (Invitrogen, Munich, Ger-
many).
Cell lysates were prepared in an SDS lysis buffer (1.5 M Tris-
HCl, pH 6.8, 20% SDS, 10% Glycerol). The cells were treated for
16 h with 10 mM MG132 and 20 mM calpain I or for 24 h with
500 nM lactacystin.
Western blot analysis was performed using the anti-RARa (C-
20 - Santa Cruz Biotechnology, Santa Cruz, USA), anti-GFP (FL -
St. Cruz), anti-c-ABL (24-11, St. Cruz Biotechnology, Santa Cruz,
USA) and anti-phospho-ABL (Tyr245, Millipore, Billerica, USA),
anti-GAPDH (FL-335 - St. Cruz), and anti-tubulin (Ab-4,
NeoMarkers, Thermo Scientific Inc., Kalamazoo, USA) antibod-
ies. The membranes were blocked in 5% low-fat milk and washed
in TBS/0.1% Tween20 (TBS-T). The antibodies were diluted in
either 5% low-fat dry milk (anti-GFP, anti-tubulin), 0,5% low-fat
dry milk (anti-GAPDH, anti-RARa) or TBS-T (anti-phospho-
ABL, anti-c-ABL, anti-HA). Horseradish peroxidase-conjugated
secondary antibodies (St. Cruz Biotechnology, Santa Cruz, USA)
were diluted 1:2000 in 5% low-fat dry milk or TBS-T.
IL3 starvation assay in BA/F3 cells
BA/F3 cells were infected with retrovirus, as previously
described.[14] The cells were cultured without IL3 for five days.
Each day, the cells were counted, and the GFP content was
measured by FACS.
Size exclusion chromatography
Proteins were translated using the TNTHT7 Quick Coupled
Transcription/Translation System (Promega, Madison, USA)
according to the manufacturer’s instructions. The protein solution
was diluted with the chromatography running buffer.
Phoenix cells were transiently transfected using the calcium
phosphate transfection method, as previously described [4]. After
3 days, the cells were incubated with 10 mM MG132 for 6 h. The
cells were lysed with IPH lysis buffer (100 mM Tris, pH 8.0,
150 mM NaCl, 5 mM EDTA, 5% NP40) supplemented with
Protease Inhibitor Cocktail Set I (Merck KGaA, Darmstadt,
Germany) and Phosphatase Inhibitor Cocktail Set II (Merck
KGaA, Darmstadt, Germany) and sonified (Amplitude: 20%,
pulse: 1 sec, pause: 2 sec, duration: 30 sec) by a Digital Sonifier
W-250D (Branson Ultrasonic Cooperation, Danbury, USA).
Liquid chromatography was performed at 4uC using a Superdex
200 10/300 GL size exclusion column (GE-Healthcare, Upsala,
Sweden) with a running buffer (20 mM Tris, pH 8.0, 175 mM
NaCl, and 5% glycerol) at a flow rate of 0.4 ml/min. Half-
milliliter fractions were collected, concentrated using StrataClean
Resin (Agilent Technologies, Santa Clara, USA) and analyzed by
western blot. Protein bands were then detected using the
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densitometric analysis was performed using Quantity One
software (Bio-Rad, Munich, Germany).
Immunoprecipitation
Using the calcium phosphate transfection method, the 293 cells
were transiently transfected with the PCDNA3 vector expressing
PML/RARa orPLZF/RARa (X-RARa, whereXcorrespondedto
either PML or PLZF) combined with HA-PCC, HA-POZ or HA-
BCC constructs, as previously described [4]. Empty vectors or a
vector containing only the HA tag were used as controls. The 293
cells were then lysed in buffer containing 100 mM NaCl, 50 mM
Tris-HCl, 50 mM HEPES, 1 mM EDTA, 100 mM sodium
pyruvate, 0.1% NP-40, 5 mM sodium orthovanadate and protease
inhibitors (Roche Complete, Basel, Switzerland). Lysates were
precleared for 1 h at 4uC on Protein-G Sepharose (GE-Healthcare,
Upsala, Sweden). An anti-hemagglutinin (anti-HA) protein affinity
matrix composed of rat monoclonal anti-HA antibody (clone 3F10)
covalently coupled to agarose beads (Roche,Basel, Switzerland) was
used to precipitate the HA-tagged peptides. The beads were
subsequently washed in the buffer described above and re-
suspended in LDS loading buffer containing a reducing agent;
10% of the input served as a control. The samples were analyzed by
western blot and stained with an anti-HA antibody to detect the
peptides and with anti-RARa antibodies to detect X-RARa.
Isolation of murine Sca1
+/lin
2 hematopoietic progenitor
cells (m-HPCs), retroviral infection, colony assay and
differentiation analysis
The isolation and retroviral infection of the m-HPCs were
performed as previously described [15]. The infection was
repeated in 3 alternating rounds for each construct. Infected cells
were assessed by GFP detection.
The m-HPCs [15] were cultivated in DMEM supplemented
with 1% penicillin/streptomycin, 1% L-glutamine (Gibco-BRL,
Invitrogen, Munich, Germany) 10% FCS, mIL-3 (20 ng/mL),
mIL-6 (20 ng/mL) and mSCF (100 ng/mL) (StemCell Technol-
ogies, Vancouver, Canada). On day 3, the cells were plated in
triplicate at a concentration of 5000 cells/ml in semisolid
methylcellulose without EPO (Stem Cell Technologies, Vancou-
ver, BC Canada), supplemented with cytokines from StemCell
Technology and incubated at 37uC with 5% CO2. After a 10-day
incubation, the cells were counted and analyzed for differentiation
by morphological analysis and FACS. The cells were washed, and
the surface markers Sca1, cKIT, Gr-1 and Mac-1 were assessed
with PE-conjugated antibodies (Becton Dickinson, Heidelberg,
Germany) and detected by FACS. A total of 100,000 cells were
cytofuged and stained with a Wright-Giemsa solution to morpho-
logically analyze their differentiation state.
Reverse Transcriptase-PCR (RT-PCR)
Total RNA and first-strand cDNA were obtained from the m-
HPCs (3 days after infection) according to standard protocols. PCR
was conducted following standard protocols using a Robocycler
(Perkin Elmer Cetus, Norwalk USA). The PCR products were
analyzed by agarose gel electrophoresis. The quality of the cDNAwas
assayed by a b-actinPCRamplification.Forthespecificamplification
of the breakpoints following the primer, the following were used: for
PML/RARa,P M L - A 1 ,5 9-CAGTGTACGCCTTCTCCATCA-39
and RARa-B, 59-GCTTGTAGATGCGGGGTAGA-39 [18]; for
PLZF/RARa,P L Z F - 2 4 ,5 9-GCTGACGCTGTATTGAGC-39 and
RARa-24, 59-ACATGCCCACTTCAAAGC-39.
Results
Targeting PML/RARa and PLZF/RARa through peptide
interference
We previously showed that the PLZF/RARa oligomerization is
responsible for repressing promoter activity [13] and biological
function, as indicated by the inability of PLZF/RARa to induce the
differentiation block and the aberrant stem cell capacity through the
expression of oligomerization defective PLZF/RARa mutants.
To target the oligomerization domains of PML/RARa and
PLZF/RARa, we used a peptide that represents the functionally
‘‘coiled-coil’’ oligomerization surface of PML/RARa (PCC; aa.
221–361) or the POZ domain of PLZF (aa. 1–125), which
represents the oligomerization surface of PLZF/RARa.
As shown previously, the forced oligomerization of ABL kinase
causes IL3-independent growth in Ba/F3 cells [14]. To investigate
whether the peptides were able to inhibit the biological function of
the fusion proteins, we exploited the ability of the oligomerization
interfaces fused to ABL to cause growth factor-independent Ba/F3
cell growth. We generated constructs to co-express the fusion
protein and the respective peptide. We subcloned the PCC and the
POZ peptides fused to GFP into retroviral vectors expressing
PCC/ABL and POZ/ABL fusion proteins, respectively.
To assess the functionality, these constructs were transduced
into Ba/F3 cells, and the derived cells were tested for IL3-
independent growth (Figure 1C).
As expected, the Ba/F3 cells expressing PCC/ABL or POZ/
ABL grew in the absence of IL3, whereas cells carrying empty
retrovirus alone (Mock) did not. In contrast, the cells co-expressing
PCC-GFP or POZ-GFP (also called interfering peptides) showed
inhibited cell growth in the absence of IL3 (Figure 1A).
As controls, we used GFP alone or the interfering peptide of the
other fusion protein. In this way, we were able to show that the
growth inhibition was specifically due to the co-expression of the
peptide that targeted the oligomerization. The growth of the Ba/
F3 cells expressing PCC-ABL was suppressed with the PCC-GFP
peptide, but not with GFP alone or the POZ-GFP. Similar results
were observed with the POZ/ABL construct and the respective
controls (Figure 1 A, C). In these experiments, the infection
efficiency was different for each viral vector. We repeated the
experiments with the cells expressing the same amount of GFP at
the starting point. As shown in Figure S1, we observed similar
results to those previously obtained. To assess the expression of the
proteins, we performed western blotting with the cell lysates of
these cells. PCC-ABL and POZ-ABL were expressed in the
retrovirus-producing Phoenix cells (Figure 1B). The phosphory-
lated ABL protein was also detected in these cells, appearing less
phosphorylated in the presence of the corresponding inhibitory
peptide (Figure 1B). In the infected Ba/F3 cells, there was no or
little expression of these proteins in the presence of the
corresponding interfering peptide. Only a small amount of the
protein was detected with the anti-phospho-ABL antibody in the
Ba/F3 cells. These data show that the proteins were correctly
expressed in the Phoenix cells. In contrast, the expression was not
detectable in Ba/F3 cells, most likely due to a cell type-dependent
protein degradation, as discussed below.
The interfering peptides bind to the X-RARa fusion
protein
The PCC or POZ domains are responsible for the homomeric
binding of PML/RARa and PLZF/RARa, respectively [7,13,19].
Our interfering peptides, which bind to these domains, should be
able to complex with X-RARa (Figure 2A). To test this hypothesis,
we co-expressed HA-tagged PCC/POZ and X-RARa in the 293
Targeting APL-Related Fusion Proteins
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expected, both fusion proteins co-immunoprecipitated with the
corresponding interfering peptide (Figure 2B). For PML/RARa
and PCC, the binding appeared to be stoichiometric, as shown by
the use of different amounts of PCC. Another unrelated ‘‘coiled-
coil’’ domain (BCC; from BCR) and HA alone demonstrated no
binding to PML-RARa. Although the BCC lane was dark, this
darkness was due to the background, as no specific band was
visible. This result shows that the interaction is specific (Figure 2B).
Strong and specific binding was shown for PLZF/RARa and POZ
(Figure 2C). In conclusion, these data show that each peptide is
able to bind to the related fusion protein.
Figure 1. Co-expression of PCC/POZ-GFP reverses IL3-independent growth in PCC/ABL- or POZ/ABL-positive BA/F3 cells. A, Infected
BA/F3 cells were cultivated for 5 days without IL3. The total cell count and FACS measurement of the GFP signal were ascertained daily, n=3. The
upper panels represent the GFP positive population accumulation, and the lower panels represent the IL3-independent growth of the Ba/F3 cells
expressing the ABL fusions in the presence or absence of the related peptides or GFP alone, as indicated. Mock: PIDE vector without BCC-ABL or POZ-
ABL, expressing only GFP. B, Western blot of whole cell lysates of Phoenix and BA/F3 cells probed for ABL (a-ABL), phospho-ABL (a-ABL*) and GFP (a-
GFP). Control: empty vector. C, Schematic diagram of IL3 growth dependency, as shown for PCC. By fusing ABL to PCC, BA/F3 cells can grow in the
absence of IL3. The introduction of PCC-GFP inhibits the PCC/ABL complex formation and restores IL3-dependent growth.
doi:10.1371/journal.pone.0048636.g001
Figure 2. PCC and POZ bind to PML/RARa and PLZF/RARa, respectively. A, Theory for the peptide binding to X-RARa, as exemplified by POZ
and PLZF/RARa. By binding the oligomerization domain of PLZF/RARa, POZ disables the self-oligomerization and the high-molecular-weight complex
formation. B, C, HA-tagged peptides were co-expressed with PML/RARa or PLZF/RARa in the 293 cells through the transfection of the corresponding
combination of pCDNA3 vectors with calcium phosphate. An HA-empty plasmid and an HA-tagged BCC (coiled-coil domain of BCR) were used as a
specificity control. In B, PCC was transfected at two different concentrations, 5 and 10 mG DNA (first and second BCC lane, respectively).
Immunoprecipitation (IP) was performed with an anti-HA matrix. Western blots were probed with a-HA and a-RARa antibodies.
doi:10.1371/journal.pone.0048636.g002
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weight complexes formed by the X-RARa fusion protein
Previously, we showed that the PLZF/RARa complex forma-
tion is essential for the incorrect gene regulation caused by PLZF/
RARa, resulting in a differentiation block [13]. We tested the
ability of X-RARa to form complexes in the presence of the
interfering peptide. For the in vitro analysis, we translated X-RARa
together with either the related peptide or a mock control and
analyzed the protein size using size exclusion chromatography. As
shown in Figure 3, the in vitro translated PML/RARa in the
presence of the HA peptide alone formed a complex with a
maximum peak eluting between 381 and 484 KD. The presence of
the HA-PCC peptide increased the complex size to 670 KD. This
increase was not observed with the BCC domain. For PLZF/
RARa, the in vitro translated protein formed a complex that eluted
with a maximum peak at fraction 22, with a molecular weight of
236–300 KD. The elution peak was only partially reduced to
fraction 23 (185–236 KD) in the presence of the HA-POZ peptide.
Fractions 17 to 20 of PLZF/RARa had a higher degree of
intensity compared with those fractions eluting in the presence of
the HA-POZ peptide. As a control, we used a POZ mutant of
PLZF/RARa, PLZFL103E/RARa. As reported previously [13],
this mutant lost the ability to form HMW complexes and eluted at
fraction 25 with a molecular weight less than 136 KD, which most
likely represented the monomeric form of the protein (Figure 3B).
We proceededtovalidatetheseresultsintheintracellularcontext.
We co-expressed X-RARa with the related interfering peptide in
Phoenix cells. After lysis under non-denaturing conditions, the
protein extracts were subjected to a chromatographic analysis.
Under these conditions, the PML/RARa fusion protein formed a
complex that eluted in fractions 17 to 21, similar to the results
previously observed [7,20]. In the presence of PCC, the complexes
eluted with a high peak at fraction 16 (Figure 3C), confirming the
results obtained by the in vitro studies, but with an overall higher
molecular weight. For PLZF/RARa, the complex eluted in fraction
16. In the presence of the HA-POZ peptide, this protein was
destabilized, eluting in the lower molecular weight fractions.
In summary, these data show that the two X-RARa complexes
were modified by the presence of the peptide in different ways: the
PML/RARa complex became augmented, whereas the PLZF/
RARa complex was destabilized.
The interfering peptides target the X-RARa fusion protein
through protein degradation
To further investigate the effects of the interfering peptides on
the leukemic phenotype, viral supernatant from the Phoenix cell
line was used to infect Sca1
+/lin
2 murine hematopoietic
progenitor cells (m-HPCs) with the indicated constructs.
The infection efficiency of the retroviral supernatant in Ba/F3
cells was measured. The supernatant was then used to infect the m-
HPCs. Infected Ba/F3 cells were lysed and analyzed by western blot
to confirm the expression of the expected proteins. We observed that
PML/RARa and PLZF/RARa were not detectable in the samples
when the interfering peptide was co-expressed (Figure 4 A–B).
To investigate if the PML/RARa and PLZF/RARa fusion
proteins were not detected in the presence of the interfering
peptides due to a proteasomal degradation, we treated the cells
with proteasome inhibitors. The infection efficiency of these cells
was measured with FACS as the percentage of GFP-positive cells
(Figure 4F). We observed that the PML/RARa protein was
stabilized by the presence of MG123 and the calpain I inhibitor
but the protein degradation was not completely impaired
(Figure 4C). In addition, the PML/RARa protein co-expressed
with GFP alone or POZ-GFP appeared to be stabilized in the
presence of the inhibitors (Figure 4C). The degradation of PLZF/
RARa in the presence of the POZ-GFP peptide appeared to be
not inhibited by MG 132 or Calpain I (Figure 4D). A more specific
and irreversible proteasome inhibitor for PLZF/RARa, Lactacys-
tin, appears to at least partially restore the expression of PLZF/
RARa in the presence of POZ-GFP (Figure 4E). These data
strongly suggest that the interfering peptides partially trigger the
proteasomal degradation of the PML/RARa and the PLZF/
RARa fusion proteins.
SUMO modifications of PML-RARa are indispensable for
the PCC-GFP peptide-dependent degradation
PML/RARa is modified by PIC1/SUMO prior to degradation
[21,22]. To test whether this modification plays a role in the
interfering peptide-induced degradation of PML/RARa, we used
a mutant of PML/RARa (PML3-160/RARa) in which the three
SUMO-binding sites were mutated. As shown in Figure 4 (panel
G), we observed a strong reduction in the PML/RARa protein
band intensity in the presence of the PCC-POZ peptide, while the
PML3-160/RARa mutant showed no significant change in the
presence of the peptide. In conclusion, we suggest that the SUMO
modification is indispensable in the degradation of PML/RARa
induced by the PCC peptide.
The interfering peptides ameliorate the X-RARa-induced
myeloid differentiation block in murine hematopoietic
stem cells
The ability of the interfering peptide to influence the
differentiation block and the aberrant self-renewal induced by
X-RARa was investigated.
X-RARa in the presence or the absence of the corresponding
interfering peptide or an unrelated control peptide was expressed
in early m-HPCs and the state of differentiation was measured. A
diagram of the experimental strategy is shown in Figure 5A. The
infection efficiency of the control cells harboring the PINCO
empty (control cells) was 71%. For the fusion construct, the
infection efficiency was between 21% and 32%, as shown in
Figure 5B. To determine whether the fusion proteins were
effectively expressed in the m-HPCs, RNA was extracted, and
RT-PCR was performed using primers directed against the
specific translocation break point (for PML/RARa PML-A1 and
RARa-B [18]; for PLZF/RARa with the primers PLZF-24 and
RARa-24; see methods section for sequences). As expected, we
were able to detect the transcripts (Figure 5C). We found that X-
RARa caused a differentiation block in the m-HSCs, which was
reversed by the introduction of the interfering peptide, as
represented as the larger and differentiated cells shown in
Figure 5D. The co-expression of the interfering peptide led to
an increased expression of Gr-1 and Mac-1 surface markers to
levels comparable to the control cells, indicating an induced
differentiation (Figure 5 E–F). A reduction in the expression of
Sca1 and c-Kit indicated a reduction in the stem cell compartment
(Figure 5 E–F). This effect was specific because the unrelated
control peptides did not show a similar effect.
In summary, the PML/RARa- and PLZF/RARa-related
differentiation block in the m-HPCs was reverted by co-expressing
PCC-GFP or POZ-GFP, respectively.
The interfering peptides abrogate the X-RARa-aberrant
replating efficiency in murine hematopoietic stem cells
To investigate if the interfering peptides were able to abrogate
the aberrant replating efficiency of PML/RARa- and PLZF/
Targeting APL-Related Fusion Proteins
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iments with the infected m-HPCs expressing PML/RARa or
PLZF/RARa in the absence or presence of the respective
interfering GFP peptides, as discussed above (Figure 5A). The
PCC-GFP peptide diminished the colony numbers in each
passage, abrogated the capacity of PML/RARa-expressing cells
to be replated more than 4 passages (Figure 6B) and restored the
normal phenotype. The same effect was observed with PLZF/
RARa. The POZ-GFP co-expression strongly inhibited the colony
numbers at passages 2 and 3 and did not permit replating more
than 4 times (Figure 6C).
These data show that the interfering peptides can effectively
target the X-RARa fusion proteins and abolish their serial
replating capacity.
Discussion
In this work, we targeted APL-related fusion proteins using
interfering peptides directed specifically against the oligomeriza-
tion domain.
To assess this approach in a biological system, the ability of the
protein kinase ABL to become activated if fused to an
oligomerization surface [14] was determined and used as a proof
Figure 3. PCC and POZ influences on the HMW complex formation of PML/RARa and PLZF/RARa, respectively. A and B, Size-exclusion
chromatography fractions of in vitro translated PML/RARa (A) or PLZF/RARa (B) and HA-tagged peptide. Fractions were analyzed by western blot (on
the right) and probed against RARa. The densitometric analysis of the western blot is shown on the left side as a percentage of the entire signal. C
and D, Size-exclusion chromatography of the Phoenix whole cell lysates overexpressing PML/RARa (C) or PLZF/RARa (D) and GFP-tagged peptide.
Fractions were analyzed by western blot (WB) and probed against RARa (a-RARa) (lower part). The densitometric analysis of the western blot is shown
in the upper part as a percentage of the entire signal. HA-mock: control empty vector. Input (I), eluted fractions 14 to 29. The numbers above the
arrows represent the molecular weight (KD) of the proteins used for the MW calibration: 136 KD for the BSA dimer, 440 KD for Ferritin, and 670 KD for
Thyroglobulin.
doi:10.1371/journal.pone.0048636.g003
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coil’’ of PML or the BTB/POZ domain of PLZF to ABL. These
fusion proteins were previously reported to induce growth factor-
independent Ba/F3 growth [14].
With this approach, we showed that the co-expression of the
interfering peptides targeted against the oligomerization domain
abolishes the capability of the fusion protein to induce the growth
factor-independent phenotype in Ba/F3 cells.
This approach represents an effective and easy method that can
be reproduced with different oligomerization surfaces to test the
ability of peptides and drugs to interfere with protein oligomer-
ization.
The biological activity of the PML/RARa and PLZF/RARa
fusion proteins depends on the presence and the integrity of their
oligomerization domains [9,13,23].
We first tested the ability of the interfering peptides to bind to
their respective fusion protein by co-immunoprecipitation exper-
iments using HA-tagged peptides and found that the peptides
specifically bound to their respective fusion proteins. We
performed several immunofluorescence experiments, but we failed
to see a co-localization between the fusion proteins and the
peptides, probably due to the fact that the expression of the fusion
protein is so strong repressed by the co-expression of the
interfering peptide. We believe that the co-immunoprecipitation
indicates that the peptide bound to the corresponding protein in
our system. Multiple reports have already demonstrated the
binding to the oligomerization surface ([7][24][20][10][13]. We
then tested the effect of the peptides on the fusion protein complex
formation. We showed that the PCC does not destroy the HMW
complex formation but rather generates complexes with a higher
molecular weight in combination with PML/RARa. This finding
was surprising, but in accordance with other mechanisms involved
in the PML/RARa inactivation, such as the effect of arsenic
trioxide. Arsenic trioxide is able to directly bind to the N-terminal
region of PML and induce an enhanced oligomerization, followed
by a subsequent degradation upon the recruitment of SUMO [25].
The forced expression of an isolated ‘‘coiled-coil’’ domain can
be assumed to bind with higher intensity to the wild type, inducing
a SUMO-dependent proteasomal degradation. The binding of
PCC and SUMO to PML/RARa may have caused the
augmented complex sizes that were observed in our experiments.
In this work, we showed that the SUMO modification of PML/
RARa is indispensable for protein degradation, as indicated by the
failed degradation of the SUMO-mutated PML/RARa in the
presence of the interfering peptide.
The co-expression of PLZF/RARa and the POZ-GFP peptide
interfered with the formation of the HMW complexes, reducing
their size to a lower molecular weight. This observation is
consistent with a previous report on the AML1/ETO HMW
complex inhibition by an interfering peptide [26].
We also tested the effect of the peptide on the biology of X-
RARa. PML/RARa and PLZF/RARa are known to induce
specific phenotypes if expressed in Sca1+/Lin2 hematopoietic
murine progenitor cells. In m-HPCs, X-RARa blocks terminal
differentiation and causes abnormal self-renewal. In this work, we
investigated the ability of the interfering peptides to inhibit the
leukemic phenotype induced by X-RARa and found that the co-
expression of these peptides with their respective X-RARa
Figure 4. PM/RARa and PLZF/RARa, degrade in the presence of PCC and POZ, respectively. A and B, Western blot of the whole cell lysates
of PML/RARa-( A) or PLZF/RARa (B)-positive Phoenix and BA/F3 cells probed against RARa (a-RARa) and GFP (a-GFP). C and D, BA/F3 cells were
treated with 10 mM MG132 or 20 mM Calpain I for 16 h. Control: empty vector; tubulin: loading control. E. BA/F3 cells were treated with 500 nM
Lactacystin for 24 h. Control: empty vector; GAPDH: loading control. F, The infection efficiency, measured as the percentage of GFP-positive cells, of
the Ba/F3 cells after infection with PINCO (control) or PIDE carrying PLZF/RARa alone or in combination with GFP, GFP-POZ or GFP-PCC or PML/RARa
alone or in combination with GFP, GFP-POZ or GFP-PCC peptides, as indicated. G, Western blot of the Phoenix whole cell lysate expressing PML/RARa
or a sumoylation-deficient mutant (PML3-160/RARa) PCC-GFP or GFP, probed with a-GFP, a-RARa and a-GPADH as a loading control. The image
shown is a representative of three separate experiments.
doi:10.1371/journal.pone.0048636.g004
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Schematic diagram of the experiment conditions. Sca1
+/lin
- murine bone marrow cells were isolated and infected with retroviral vectors containing
PML/RARa or PLZF/RARa and GFP or PCC/POZ-GFP and then analyzed for differentiation. B, The infection efficiency, measured as the percentage of
the GFP-positive cells to the retrovirally infected cells. C, Reverse transcriptase-PCR of the retrovirus-infected Sca
+/lin
2 bone marrow cells for PML/
RARa and PLZF/RARa. Control: b-Actin. D, GIEMSA staining of Sca
+/lin
2 bone marrow cells seven days after infection with retroviral vectors. E, FACS
analysis of the Sca1
+/lin
2 bone marrow cells infected with PML/RARa and GFP or PCC/POZ-GFP. Mock: empty vector. F, FACS analysis of the Sca1
+/
lin
2 bone marrow cells infected with PLZF/RARa and GFP or PCC/POZ-GFP. Mock: empty vector.
doi:10.1371/journal.pone.0048636.g005
Figure 6. PCC and POZ reverse the proliferation capacity of PML/RARa- and PLZF/RARa-positive murine hematopoietic stem cells.
A, Schematic diagram of the experimental conditions. Sca1
+/lin
2 bone marrow cells were isolated and infected with retroviral vectors containing
PML/RARa or PLZF/RARa and GFP or PCC/POZ-GFP. Infected cells were plated in methylcellulose on day 3. Colony counts and replating were
measured every 10 days. B and C, Colony count of Sca1
+/lin
2 bone marrow cells infected with PML/RARa (B) or PLZF/RARa (C) and GFP or PCC/POZ-
GFP cultured in methylcellulose. Mock: empty vector.
doi:10.1371/journal.pone.0048636.g006
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renewal. A similar effect was shown by interfering with the
oligomerization of the AML1/ETO fusion protein using a peptide
designed to bind to the oligomerization domain [26]. Targeting
the fusion protein/co-repressor contact was reported to restore a
differentiation response in leukemia cells expressing PML/RARa
or AML1/ETO [27].
The expression of interfering peptides specifically induced the
degradation of the PML/RARa and PLZF/RARa protein. A
similar result was previously described for interfering peptides
designed to bind to the fusion protein/co-repressor contact region
of PML/RARa [27]. The proteasomal inhibitors abolished the
degradation, suggesting that the fusion protein is degraded by the
proteasome. The use of MG123 or Lactacystin for PLZF/RARa
only partially restored the fusion protein expression, suggesting
that this degradation is only mediated in part by the proteasome.
One possible mechanism might be that the ‘‘coiled-coil’’ domain
of PML is a target for the E3 Ubiquitin-Ligase SIAH1/2, which
mediates the degradation of PML/RARa [28]. In our study, we
showed that the complex formed by PML/RARa increases in size,
suggesting that the addition of PCC peptides triggers a degrada-
tion that is dependent upon a binding to PIC/SUMO1.
In the first part of this work, we showed a promising model for
screening small peptides or low-molecular-weight compounds
designed to block oligomerization using oligomerization domains
fused to the ABL kinase. This approach could provide a significant
improvement for the therapeutic treatment of acute myeloid
leukemia and other diseases in which protein oligomerization plays
a dominant role.
We showed that the X-RARa oligomerization domain is a
promising target for molecular intervention. The oligomerization
domain in the fusion protein was a key component contributing to
the fusion protein’s oncogenic properties. The targeting of the
oligomerization led to an inhibition of the leukemic phenotype and
was accompanied by a strong protein degradation that efficiently
destroyed the oncogenicity of the fusion protein.
Supporting Information
Figure S1 Co-expression of PCC/POZ-GFP reverses
IL3-independent growth in PCC/ABL- or POZ/ABL-
positive BA/F3 cells. A–D Infected BA/F3 cells were cultivated
for 6 days without IL3. The total cell count and FACS
measurement of the GFP signal were ascertained daily, n=2.
The A–B panels represent the GFP positive population accumu-
lation, and the C–D panels represent the IL3-independent growth
of the Ba/F3 cells expressing the ABL fusions in the presence or
absence of the related peptides or GFP alone, as indicated. E–F,
Western blot of the whole cell lysates of the Phoenix and BA/F3
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